Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

Completed · Phase 2 · Has a placebo group

Conditions studied: Alcoholism, Schizophrenia

In brief

This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia. Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also, glycine will improve negative symptoms and cognitive deficits in schizophrenia.

Key facts

Study ID

NCT00338598

Run by

Yale University

People needed

20

Starts

2003-06-01

Expected to finish

2015-12-01

Last updated by the study team

2018-01-17

Who can join

Age: 21 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-IV diagnosis of schizophrenia or schizoaffective disorder
• DSM-IV diagnosis of alcohol dependence
• Stable treatment with typical or atypical antipsychotics

You may not qualify if…

• Axis I diagnosis other than alcohol dependence, schizophrenia, schizoaffective disorder, OCD, and PTSD.
• current drug dependence
• evidence of significant hepatocellular injury evidence by abnormal SGOT or SGPT levels
• history of seizures
• diabetes and medical conditions that would alter glycine metabolism
• positive pregnancy test
• treatment with clozapine, naltrexone or disulfiram

Where it is running

• VA Connecticut Healthcare System — West Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.